Related Experiment Videos
Comparison of the tumor inhibiting effects of three histamine H2-receptor antagonists
Abstract:
Three histamine H2-receptor antagonists, Cimetidine, Metiamide and Ranitidine, were tested for their inhibitory effect on two experimental bowel cancer models. In the first model mitotic rates were measured in dimethylhydrazine-induced tumors of rat colon and in the second model volumetric changes in human large bowel cancer xenografts were assessed. In tumors of rat colon all three drugs were able to suppress mitotic activity, but the effects of Metiamide and Ranitidine were more prolonged than that of Cimetidine in each of two lines of human bowel cancer that were used. Metiamide and Ranitidine were also more effective growth inhibitors than was Cimetidine.
Insights
Three histamine H2-receptor antagonists demonstrated inhibitory effects on experimental bowel cancer models. Metiamide and Ranitidine showed more prolonged suppression of mitotic activity and effective growth inhibition compared to Cimetidine.
Area of Science:
- Oncology
- Pharmacology
Background:
- Histamine H2-receptor antagonists are used to treat various conditions.
- Their potential role in cancer therapy is an area of ongoing research.
Purpose of the Study:
- To evaluate the inhibitory effects of three histamine H2-receptor antagonists (Cimetidine, Metiamide, and Ranitidine) on experimental bowel cancer models.
Main Methods:
- Assessed mitotic rates in dimethylhydrazine-induced rat colon tumors.
- Measured volumetric changes in human large bowel cancer xenografts.
- Compared the efficacy of Cimetidine, Metiamide, and Ranitidine.
Main Results:
- All three drugs suppressed mitotic activity in rat colon tumors.
- Metiamide and Ranitidine exhibited more prolonged suppression of mitotic activity than Cimetidine.
- Metiamide and Ranitidine were more effective growth inhibitors of human bowel cancer xenografts than Cimetidine.
Conclusions:
- Histamine H2-receptor antagonists, particularly Metiamide and Ranitidine, show promise as potential agents for inhibiting bowel cancer growth.
- Further research is warranted to explore their therapeutic potential in colorectal cancer treatment.